



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit [go.covermymeds.com/OptumRx](http://go.covermymeds.com/OptumRx) to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

## Zepatier® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting <b>brand</b>			Directions for Use:		
<input type="checkbox"/> Check if request is for <b>continuation of therapy</b>					
Clinical Information (required)					
<b>Select the diagnosis below:</b> <input type="checkbox"/> Chronic Hepatitis C virus (HCV) <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
<b>Clinical Information:</b> Document the patient's HCV genotype:* _____ Will medical records (e.g., chart notes, laboratory values) be submitted documenting the patient has a diagnosis of HCV genotype 1a, 1b, or 4?* <input type="checkbox"/> Yes <input type="checkbox"/> No <i>*Please note: Chart documentation of the above is required to be submitted along with this fax.</i> Select the patient's treatment experience: <input type="checkbox"/> Patient is treatment-naïve <input type="checkbox"/> Patient has prior failure to peginterferon alfa plus ribavirin treatment <input type="checkbox"/> Patient has prior failure to peginterferon alfa plus ribavirin treatment plus a HCV NS3/4A protease inhibitor (e.g., boceprevir, simeprevir, or telaprevir) Will Zepatier be used in combination with ribavirin? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient been tested for the presence of NS5A resistance-associated polymorphisms? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have baseline NS5A resistance-associated polymorphisms (i.e., polymorphisms at amino acid positions 28, 30, 31, or 93)? <input type="checkbox"/> Yes <input type="checkbox"/> No Select if Zepatier is prescribed by or in consultation with one of the following specialists: <input type="checkbox"/> Gastroenterologist <input type="checkbox"/> HIV specialist certified through the American Academy of HIV Medicine <input type="checkbox"/> Hepatologist <input type="checkbox"/> Infectious Disease Specialist Will the patient be receiving Zepatier in combination with another HCV direct acting antiviral agent (e.g., Sovaldi [sofosbuvir], Olysio [simeprevir])? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have moderate to severe hepatic impairment (e.g., Child-Pugh Class B or C)? <input type="checkbox"/> Yes <input type="checkbox"/> No Select if the patient has had trial and failure, intolerance, or contraindication to the following: <input type="checkbox"/> Epclusa (sofosbuvir/velpatasvir) <input type="checkbox"/> Harvoni (ledipasvir/sofosbuvir) <input type="checkbox"/> Mavyret (glecaprevir/pibrentasvir) Is this for continuation of prior Zepatier (elbasvir/grazoprevir) therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Zepatier\_Comm\_2019Mar-W



**Zepatier<sup>®</sup> Prior Authorization Request Form (Page 2 of 2)**  
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

**Quantity Limit Requests:**

What is the quantity requested per DAY? \_\_\_\_\_

**What is the reason for exceeding the plan limitations?**

- Titration or loading dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- Other: \_\_\_\_\_

**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?**

---

---

Please note:

This request may be denied unless all required information is received.  
For urgent or expedited requests please call 1-800-711-4555.  
This form may be used for non-urgent requests and faxed to 1-800-527-0531.